ArticleFrontiers in pediatrics2026
Epoprostenol as an alternative anticoagulant for pediatric aquadex therapy: a safe and feasible option.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Aquadex ultrafiltration system offers a low extracorporeal volume option for the pediatric population. To maintain circuit patency, it relies on conventional anticoagulation, and data on alternative anticoagulation strategies are limited. Epoprostenol, a prostacyclin analog that inhibits platelet aggregation, may provide a safe alternative. The objective of this study was to describe the use of epoprostenol as the sole anticoagulant for Aquadex ultrafiltration therapy in critically ill children and to evaluate its safety, feasibility, and impact on circuit patency. Methods: We conducted a single-center retrospective study of children (<18 years) who received Aquadex therapy with epoprostenol anticoagulation between September 2022 and September 2025 at UPMC Children's Hospital of Pittsburgh. Safety and efficacy were assessed by platelet count, bleeding events, vasoactive-inotropic scores (VIS), and circuit performance. Results: Forty-six patients underwent 52 treatments. Median (IQR) age was 35.5 (12.5-114) months. Primary indications were fluid overload (88.5%) and acute kidney injury (11.5%). The median therapy duration was 3 [2-9] days, with a filter-to-day ratio of 0.5 (0.3-0.5). Platelet counts rose from a median (IQR) of 113 (×10⁹/L) prior to therapy to 126 (×10⁹/L) at 72 h, with a median of 0 [0-1] platelet transfusions per day. The median VIS was 4 [0-12] prior to therapy and 0 [0-8] at 48 h; vasoactive-inotropic requirements did not increase at any time point. No bleeding events directly attributable to epoprostenol or therapy discontinuations due to hypotension occurred. Circuit patency was maintained, with a median of 0 (0-1) interruptions per course due to clotting or clogging. Conclusions: Epoprostenol appears to be a feasible anticoagulant for pediatric Aquadex therapy, with preserved circuit function, no increase in vasoactive-inotropic requirements, and no observed bleeding events. These findings support its further evaluation as an alternative anticoagulant for pediatric Aquadex Therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.